SurModics Inc. (SRDX)

38.20
0.15 0.39
NASDAQ : Health Technology
Prev Close 38.35
Open 38.20
Day Low/High 38.20 / 38.20
52 Wk Low/High 22.35 / 40.30
Volume 3.00K
Avg Volume 38.80K
Exchange NASDAQ
Shares Outstanding 13.20M
Market Cap 506.10M
EPS 0.30
P/E Ratio 3,890.00
Div & Yield N.A. (N.A)

Latest News

Surmodics To Host Virtual Annual Meeting Of Shareholders

Surmodics To Host Virtual Annual Meeting Of Shareholders

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, will hold its Annual Meeting of Shareholders on Wednesday, February 21, at...

Surmodics Reports First Quarter Fiscal 2018 Results, Updates Fiscal 2018 Guidance

Surmodics Reports First Quarter Fiscal 2018 Results, Updates Fiscal 2018 Guidance

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 first quarter, ended December 31, 2017, and...

Surmodics To Webcast First Quarter Fiscal 2018 Earnings Conference Call On February 8

Surmodics To Webcast First Quarter Fiscal 2018 Earnings Conference Call On February 8

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its first quarter fiscal 2018...

Surmodics Receives 510(K) Clearance For Telemark™ Coronary/Peripheral Support Microcatheter From The U.S. Food And Drug Administration

Surmodics Receives 510(K) Clearance For Telemark™ Coronary/Peripheral Support Microcatheter From The U.S. Food And Drug Administration

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.

Surmodics Reports Fourth Quarter Fiscal 2017 Results And Provides Fiscal 2018 Guidance

Surmodics Reports Fourth Quarter Fiscal 2017 Results And Provides Fiscal 2018 Guidance

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2017 fourth quarter, ended September 30, 2017 and...

Surmodics To Present At Canaccord Genuity Medical Technologies and Diagnostics Forum

Surmodics To Present At Canaccord Genuity Medical Technologies and Diagnostics Forum

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Andy...

Surmodics To Webcast Fourth Quarter 2017 Earnings Conference Call On November 8

Surmodics To Webcast Fourth Quarter 2017 Earnings Conference Call On November 8

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter 2017 conference...

Surmodics Announces First Patient Enrolled In TRANSCEND Pivotal Clinical Trial For SurVeil® Drug-Coated Balloon

Surmodics Announces First Patient Enrolled In TRANSCEND Pivotal Clinical Trial For SurVeil® Drug-Coated Balloon

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced enrollment of the first patient in TRANSCEND, the pivotal clinical trial for the SurVeil ®...

Surmodics Announces Global Approvals Of .014" Low-Profile PTA Balloon Dilation Catheter

Surmodics Announces Global Approvals Of .014" Low-Profile PTA Balloon Dilation Catheter

Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it has received U.

Six-Month Data From The Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented At VIVA 2017

Six-Month Data From The Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented At VIVA 2017

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced that data from the PREVEIL early feasibility study (EFS) of the company's SurVeil ® drug-coated...

Surmodics Reports Third Quarter Fiscal 2017 Results And Updates Fiscal 2017 Guidance

Surmodics Reports Third Quarter Fiscal 2017 Results And Updates Fiscal 2017 Guidance

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2017 third quarter, ended June 30, 2017.

Surmodics Receives IDE Approval To Initiate Pivotal Trial Of The SurVeil™ Drug-Coated Balloon

Surmodics Receives IDE Approval To Initiate Pivotal Trial Of The SurVeil™ Drug-Coated Balloon

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced it has received an investigational device exemption (IDE) from the U.

Surmodics To Webcast Third Quarter 2017 Earnings Conference Call On August 3

Surmodics To Webcast Third Quarter 2017 Earnings Conference Call On August 3

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal 2017...

Surmodics To Present At Upcoming Investor Conferences

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Andy...

Surmodics Reports Second Quarter Fiscal 2017 Results, Updates Fiscal 2017 Financial Guidance

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2017 second quarter, ended March 31, 2017.

Surmodics To Webcast Second Quarter 2017 Earnings Conference Call On April 27

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its second quarter fiscal 2017...

Surmodics Appoints Lisa Wipperman Heine To Its Board Of Directors

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced the addition of Lisa Wipperman Heine to the Company's Board of Directors,...

Surmodics to Present at Oppenheimer Healthcare Conference

Surmodics, Inc. (Nasdaq:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Andy...

Surmodics Announces 2017 Annual Shareholders Meeting

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that its virtual Annual Meeting of Shareholders will be held on Tuesday,...

Surmodics Reports First Quarter Fiscal 2017 Results

Surmodics, Inc. (Nasdaq:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2017 first quarter, ended December 31, 2016.

Surmodics To Webcast First Quarter 2017 Earnings Conference Call On February 2

Surmodics To Webcast First Quarter 2017 Earnings Conference Call On February 2

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its first quarter fiscal 2017...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ARCB, BCO, BOJA, CAR, CSS, DIOD, GPX, HMTA, LPL, SENEA, SVA, TGD Downgrades: EFUT, NUS, PBFX, PESI, SRDX Initiations: CXRX, IOTS, TSRO Read on to get TheStreet Quant Ratings' detailed report:

Surmodics To Attend Piper Jaffray Healthcare Conference

Surmodics To Attend Piper Jaffray Healthcare Conference

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Andy...

Surmodics Reports Fourth Quarter Fiscal 2016 Results

Surmodics Reports Fourth Quarter Fiscal 2016 Results

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2016 fourth quarter, ended September 30, 2016.

Surmodics To Present At Canaccord Genuity Medical Technology And Diagnostics Forum

Surmodics To Present At Canaccord Genuity Medical Technology And Diagnostics Forum

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj, president and chief executive officer, and Andy...

Surmodics To Webcast Fourth Quarter And Fiscal Year 2016 Earnings Conference Call On November 16

Surmodics To Webcast Fourth Quarter And Fiscal Year 2016 Earnings Conference Call On November 16

Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter and fiscal year...

Commit To Buy Surmodics At $20, Earn 8.3% Annualized Using Options

Commit To Buy Surmodics At $20, Earn 8.3% Annualized Using Options

Investors eyeing a purchase of Surmodics Inc stock, but cautious about paying the going market price of $25.20/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2017 put at the $20 strike, which has a bid at the time of this writing of 90 cents.

Surmodics Announces Launch Of Serene® Single-Coat (SC) Solutions Offering Unmatched Lubricity And Durability To A Broader Range Of Device Applications

Surmodics Announces Launch Of Serene® Single-Coat (SC) Solutions Offering Unmatched Lubricity And Durability To A Broader Range Of Device Applications

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced the launch of a single-coat formulation of its most advanced hydrophilic medical...

TheStreet Quant Rating: C (Hold)